EMA Recommends Extension of Therapeutic Indications for Acalabrutinib By Ogkologos - June 18, 2025 807 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Sacituzumab Govitecan Plus Pembrolizumab Demonstrate Encouraging Activity in Patients with mUC... February 5, 2024 Genetic Mechanisms Identified for Acquired Resistance to Non-Covalent BTK Inhibitors March 28, 2022 A Message from the ESMO President March 17, 2020 EMA Recommends Extension of Indications for Pembrolizumab December 14, 2020 Load more HOT NEWS FDA Approves Sacituzumab Govitecan-hziy for HR-positive Advanced Breast Cancer Leveraging Extensive Real-World Data to Systematically Identify Mutations that Predict the... Study Examines Whether Blood Test Can Identify Early Cancers Open Enrollment for 2022 Affordable Care Act Plans is Here!
